Cargando…
Molecular classification and therapeutics in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) encompasses a wide variety of disease states that have to date been subgrouped and characterized based on immunohistochemical methods, which provide limited prognostic value to clinicians and no alteration in treatment regimen. The addition of rituximab to CHOP...
Autores principales: | Shimkus, Gaelen, Nonaka, Taichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936827/ https://www.ncbi.nlm.nih.gov/pubmed/36818048 http://dx.doi.org/10.3389/fmolb.2023.1124360 |
Ejemplares similares
-
Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses
por: Tan, Wei Jian, et al.
Publicado: (2021) -
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma
por: Brault, L, et al.
Publicado: (2012) -
Editorial: Insights in molecular diagnostics and therapeutics: 2022
por: Becatti, Matteo, et al.
Publicado: (2023) -
Editorial: Insights in molecular diagnostics and therapeutics: 2021
por: Becatti, Matteo, et al.
Publicado: (2022) -
Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy
por: Zhang, Pei, et al.
Publicado: (2020)